Protalix BioTherapeutics (PLX) Q3 2026 earnings review
Protalix drug shipments climb, while gout trial costs expand
Protalix BioTherapeutics, a maker of rare-disease enzyme drugs, posted a second consecutive quarter of strong partner shipments instead of an inventory pause. Product sales rose 24% from a year ago to $22 million on higher deliveries of its Fabry disease drug Elfabrio to commercial partner Chiesi, lifting net profit to $4 million. Chief executive Dror Bashan said the group expects to "meet or exceed" its $78 million to $83 million full-year revenue plan, which already sits at $76 million after nine months.
| Product sales | $21.8M +24% from a year ago |
|---|---|
| Gross margin | 64.1% +10.7 percentage points from a year ago |
| Cash and bank deposits | $48.5M up from $40.7M last quarter |
| Full-year revenue outlook | Unchanged expects to meet or beat $78–83M |
⚖️ Verdict: 🟢 Bullish
The story got better because Chiesi kept buying in the third quarter right after a heavy second-quarter restock, lifting nine-month product sales to $49 million and expanding the cash balance. One caution: clinical trial bills for PRX-115, its experimental gout drug, pushed research spending up 55%, and keeping the full-year outlook brackets unchanged leaves only $2 million to $7 million of revenue implied by the plan for the fourth quarter.
The question now is whether consecutive quarters of Elfabrio shipments reflect rising patient demand or just partner warehouse timing. If patient adoption after European and Brazilian dosing approvals is driving orders, full-year sales will beat the top of the outlook; if Chiesi only stocked its shelves early, fourth-quarter deliveries will drop. Fourth-quarter shipments and the customer breakdown in the quarterly filing will settle it.
🐂 Bull Case
Partner Orders Stayed Strong Instead of Dropping
Protalix makes enzyme replacement drugs and sells them in bulk to commercial partners, chief among them Chiesi for Elfabrio, its treatment for Fabry disease. Last quarter, Chiesi bought $14.0 million of supply mainly to build inventory, which raised the risk that third-quarter shipments would stall while the partner worked through its stock.
Instead, total product sales rose 23.5% from a year ago to $21.8 million, beating last quarter by 10.1%. The Israeli drugmaker said higher shipments to Chiesi drove the gain, while Elfabrio also won approval in Brazil for two-week and four-week dosing. Nine-month product sales reached $49.1 million, covering 89% of the middle of the full-year product outlook.
What to watch: the exact nine-month sales to Chiesi in the upcoming quarterly filing. A figure well above the $17.5 million first-half total will confirm that Chiesi ordered another large batch rather than pausing after its second-quarter restock.
Mix Shift Toward Chiesi Lifted Gross Margin
Protalix earns different margins across its three commercial buyers: Chiesi for Elfabrio, and Pfizer and Brazil's Fiocruz for Elelyso, its Gaucher disease drug. When higher-margin shipments to Chiesi make up a larger share of the quarter, profitability climbs even before total volume grows.
Cost of revenues—the expense of manufacturing the drugs—dropped by 10.7 percentage points of revenue from a year ago, falling from 46.6% to 35.9%. The company said lower shipments to Fiocruz in Brazil cut manufacturing costs, more than offsetting higher volumes to Chiesi and Pfizer, which lifted gross margin to 64.1%.
What to watch: whether cost of revenues stays near 36% of sales in the fourth quarter. If Fiocruz deliveries catch up before year-end, the mix will shift back toward Brazil and pull the gross margin down.
Cash Rose and Self-Funds the Gout Trial
Chief executive Dror Bashan pointed to $48.5 million in cash and bank deposits, calling it "a position of strength that enables us to continue advancing PRX-115 for uncontrolled gout". PRX-115 is an experimental enzyme designed to lower uric acid with fewer infusions than current gout drugs.
Cash and deposits grew by $7.9 million from last quarter, and the rare-disease developer carries no debt. At a medical meeting this quarter, Protalix presented individual patient data from its Phase 1 study showing "PRX-115 plasma levels remaining measurable for up to 85 days" after one dose, supporting the ongoing 150-patient Phase 2 trial.
What to watch: confirmation in the fourth-quarter report that Phase 2 patient enrollment finished by year-end. Staying on schedule keeps top-line results on track for the second half of 2027 without needing outside financing.
🐻 Bear Case
Gout Trial Spending Pushed Up Research Costs
Running a 150-patient Phase 2 study across five treatment arms requires heavy spending on clinical trial subcontractors. Over the first half of the year, a new Israeli government research grant program masked much of that cost increase on the income statement.
In the third quarter, net research and development expenses rose 55.0% from a year ago to $6.9 million, climbing 6.6 percentage points of revenue to 31.6%. That figure includes a $1.0 million grant reduction; by our math, gross research spending before the grant jumped 77.4% to $7.9 million, or 36.1% of revenue.
What to watch: quarterly research spending once Phase 2 enrollment completes around year-end. If subcontractor bills keep climbing while fourth-quarter product shipments slow, operating profit will turn negative in the final quarter.
Full-Year Plan Points to a Quiet Fourth Quarter
"Management expects to meet or exceed 2026 guidance for total revenues of approximately $78.0 million to $83.0 million," the company wrote, adding the "meet or exceed" phrasing while leaving the dollar brackets unchanged. Because partners order in bulk and control their own warehouses, strong shipments in one quarter often pull forward orders from the next.
- Nine-month total revenue: $75.6 million, leaving $2.4 million to $7.4 million for the fourth quarter by our math
- Nine-month product sales: $49.1 million against a combined full-year product outlook of $53.0 million to $58.0 million
- Implied fourth-quarter product sales: $3.9 million to $8.9 million by our math, down 26.2% at the middle of the range from a year ago
Keeping the ranges intact after a $21.9 million quarter means management has not ruled out a fourth-quarter pause in partner deliveries. The company noted that third-quarter changes in Pfizer and Fiocruz sales "resulted primarily from the timing of deliveries".
What to watch: whether full-year revenue beats the $83.0 million top of the outlook. Finishing inside the existing range would mean fourth-quarter shipments dropped to less than a third of the third-quarter level.
Risks this quarter didn't answer
Several standing concerns about partner demand, pipeline timing and long-term contracts received no new details in the earnings release.
- Sales by customer: the release omits exact dollar sales to Chiesi, Pfizer and Fiocruz; the quarterly filing's footnote will supply them.
- PRX-119 target disease: management previously promised to name the lead indication by mid-2026, but the release says only that PRX-119 advances "as part of a broader strategic focus on rare renal indications".
- End-market Fabry demand: no patient counts, market share or European pricing tier figures for Elfabrio, and no date for a US four-week dosing filing.
- Legacy Elelyso contracts: no update on whether Brazil's Fiocruz will meet its annual purchase minimums.
👓 Other Themes
Currency Gains and US Tax Rules Moved Net Profit
Operating in Israel while reporting in US dollars exposes the biopharmaceutical group to currency swings, cross-border tax rules and regional conflict. Net financial income rose to $0.6 million from $0.1 million a year ago on exchange rate movements between the dollar and the New Israeli Shekel and higher interest income, while US tax rules on foreign intangible income pushed income taxes to $0.7 million.
💲 Other KPIs
Stockpiles of raw materials and finished drugs rose for a fourth straight quarter, climbing 33.3% since December 2025 and 61.4% from a year ago. Higher inventory ties up working capital ahead of scheduled bulk shipments to Chiesi, Pfizer and Fiocruz.
Uncollected customer bills—cash owed by commercial partners for delivered drugs—dropped 15.7% from $16.5 million last quarter. Collecting on the second quarter's shipments helped lift the company's cash and bank deposit balance to $48.5 million while third-quarter deliveries created new receivables.
The diluted share count rose 3.4% from 80.8 million a year ago and 1.2% from 82.6 million last quarter. Because the biopharmaceutical group generated positive net income this year, outstanding options and convertible securities enter the diluted share calculation.
🔮 Guidance
Unchanged in dollar terms, though management now expects to "meet or exceed" the range, which calls for 52.6% growth at the middle of the range including the first-quarter $25.0 million Chiesi milestone. By our math, after $75.6 million in the first nine months, the middle of the range leaves $4.9 million for the fourth quarter, down 46.0% from a year ago.
Unchanged. The rare-disease drugmaker still plans for Elfabrio product sales to Chiesi to grow 51.1% at the middle of the range from $22.5 million in 2025, with management expecting to meet or beat the target. Because the press release did not break out third-quarter Chiesi sales, the fourth-quarter remainder will only be readable in the quarterly filing.
Unchanged. The plan calls for combined Elelyso sales to Pfizer and Brazil's Fiocruz to fall 26.6% at the middle of the range from $29.3 million in 2025. Last year's figure was elevated because Pfizer bought extra stock to cover its own factory issues, creating a high comparison base that unwinds this year.
❓ Key Questions
What were exact third-quarter sales to Chiesi, Pfizer and Fiocruz?
The press release reports $21.8 million in total product sales and says Chiesi drove the year-over-year gain, but withholds the customer breakdown until the quarterly filing. Those numbers show how much of the Elfabrio and Elelyso outlooks remain for the fourth quarter.
Why keep the $78–83 million range after reaching $75.6 million?
Adding "meet or exceed" while leaving the numbers unchanged implies fourth-quarter revenue could fall as low as $2.4 million to $7.4 million. Investors need to know if partners have already scheduled a fourth-quarter pause in bulk deliveries.
What disease will PRX-119 target in clinical trials?
Management previously told analysts to expect an indication and market update for its long-acting DNase I program by mid-2026. The third-quarter release repeats only that it targets rare renal diseases without naming a specific condition.
Will PRX-115 Phase 2 finish enrolling patients by year-end?
Last quarter, chief executive Dror Bashan expected enrollment in the 150-patient gout study to finish by the end of 2026. The release says enrollment continues and keeps top-line results in the second half of 2027, without confirming the year-end enrollment date.